TrialTrials2022

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION.

Jan Kloka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.